Evidence map›Paper›PMID 33833046›Full record

ArticleeNeuro

Phenotypic Differences between the Alzheimer's Disease-Related hAPP-J20 Model and Heterozygous

Daniel R Gulbranson, Kaitlyn Ho, Gui-Qiu Yu, Xinxing Yu, Melanie Das, Eric Shao, Daniel Kim, Weiping J Zhang, Krishna Choudhary, Reuben Thomas and 1 more

Open access · goldAbstract read
In one paragraph

Article in eNeuro. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. In vivo validation of late-onset Alzheimer's disease genetic risk factors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  4. bioRxiv : the preprint server for biology · 2023
    Article
  5. Inhibition of ACAT as a Therapeutic Target for Alzheimer's Disease Is Independent of ApoE4 Lipidation.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2023
    Article
  6. Article
  7. White Button Mushroom (Brain sciences · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Daniel R GulbransonGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Kaitlyn HoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Gui-Qiu YuGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Xinxing YuGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Melanie DasGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Eric ShaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Daniel KimGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158.
Weiping J ZhangDepartment of Pathophysiology, Naval Medical University, Shanghai 200433, China.
Krishna ChoudharyGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158.ORCID 0000-0002-7966-1527
Reuben ThomasGladstone Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA 94158.
Lennart MuckeGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA 94158 lennart.mucke@gladstone.ucsf.edu.
Gladstone Institutes · USSecond Military Medical University · CN

Funding

Neural network and immune cell dysfunctions in Alzheimer's disease pathogenesisRF1AG063519 · NIA · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2019 to 2020
$5.0M
Effect of Aging on Efficacy of Alzheimer-focused Therapeutic StrategiesUH3NS100128 · NINDS · J. DAVID GLADSTONE INSTITUTES · PI MUCKE, LENNART · 2018 to 2020
$504k
Automated Slide Scanner with Brightfield and Fluorescence for Stereology, FISH and Brain Connectivity MappingS10OD021717 · OD · J. DAVID GLADSTONE INSTITUTES · PI CALVERT, MEREDITH EMILY KENNEDY · 2017 to 2017
$265k
Evaluation and Disruption of Tau - GSK3β Vicious CycleF32AG062039 · NIA · J. DAVID GLADSTONE INSTITUTES · PI GULBRANSON, DANIEL · 2019 to 2021
$155k
NIA NIH HHS F32 AG062039NIA NIH HHS RF1 AG063519NIH HHS S10 OD021717NINDS NIH HHS UH3 NS100128
6 · The paper itself

Abstract

Diverse gene products contribute to the pathogenesis of Alzheimer's disease (AD). Experimental models have helped elucidate their mechanisms and impact on brain functions. Human amyloid precursor protein (hAPP) transgenic mice from line J20 (hAPP-J20 mice) are widely used to simulate key aspects of AD. However, they also carry an insertional mutation in noncoding sequence of one

Indexed as

Alzheimer DiseaseAmyloid beta-Protein PrecursorAmyloid beta-PeptidesAnimalsDisease Models, AnimalMiceMice, KnockoutMice, TransgenicPhenotypeTranscription FactorsAmyloid beta-PeptidesAmyloid beta-Protein PrecursorTranscription FactorsZbtb20 protein, mouseAlzheimer’s diseaseamyloid precursor proteinbehaviorepilepsymouse modelZbtb20

Identifiers

PMID33833046
PMCPMC8121260
OpenAlexW3149148870

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.